Drug Target Review

OCTOBER 2, 2024

Viral vectors, such as adeno-associated viruses (AAVs), are commonly used to deliver therapeutic genes to cardiac cells. RNA-based therapies, including mRNA and RNA interference (RNAi), are being explored to modulate gene expression in heart cells. Allogeneic cell therapies must avoid immune rejection.

Therapies 52

Therapies Engineering RNA Disease 52

The Pharma Data

DECEMBER 31, 2020

Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. The spike protein binds to the ACE2 receptor on human cells, which allows the virus to enter the cell.

Research 52

Research Virus Immune Response Cell Biology 52

Drug Discovery World

NOVEMBER 8, 2023

Presentations include: Marjolein van Egmond, PhD, Professor, Oncology and Inflammation, Surgery/Molecular Cell Biology and Immunology, Amsterdam UMC, on: ‘Novel FcαRI bispecific antibody immunocytokines for the recruitment of myeloid effector cells in cancer therapy’.

Engineering 162

Engineering Protein Expression Therapies Science 162

Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific.

DNA 130

DNA Clinical Trials Therapies RNA 130

Codon

APRIL 30, 2023

This works for many different cell types, and the method can also be used to deliver several different gene editors at once. It’s an easier way to get CRISPR into cells! Other methods to deliver Cas9 (like with viruses) are way less efficient, and seem to vary wildly from one cell to the next. Nature Cell Biology.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 30, 2023

This works for many different cell types, and the method can also be used to deliver several different gene editors at once. It’s an easier way to get CRISPR into cells! Other methods to deliver Cas9 (like with viruses) are way less efficient, and seem to vary wildly from one cell to the next. Nature Cell Biology.

Vaccine 52

Vaccine Engineering DNA RNA 52

Codon

APRIL 9, 2023

Read Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Read An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses. Nature Cell Biology. McGrady N.R. Gene Therapy.

Therapies 52

Therapies RNA Engineering Vaccine 52